Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CEST
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
01:39p CYTOKINETICS : Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-..
01:35p CYTOKINETICS INC : Other Events (form 8-K)
01:31p Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of C..
03/24 CYTOKINETICS : Origent Data Sciences and Cytokinetics Advance Collaboration Inte..
03/23 CYTOKINETICS INC : Other Events (form 8-K)
03/23 Origent Data Sciences and Cytokinetics Advance Collaboration Intended to Vali..
03/23 CYTOKINETICS : Announces Preclinical Data for CK-2127107 Presented at MDA Scient..
03/22 Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scien..
03/20 CYTOKINETICS INC : Other Events (form 8-K)
03/20 Cytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17
More news
Sector news : Bio Therapeutic Drugs
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ($)
Sales 2017 42,5 M
EBIT 2017 -87,8 M
Net income 2017 -84,7 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 12,3x
Capi. / Sales 2018 7,70x
Capitalization 522 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 20,1 $
Spread / Average Target 61%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Barabari Sharon A. Surrey Chief Financial Officer, Secretary & Executive VP
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.522
AMGEN, INC.12.65%121 301
CELGENE CORPORATION7.50%96 802
GILEAD SCIENCES, INC.-6.30%87 716
REGENERON PHARMACEUTIC..4.21%40 581
ACTELION LTD24.40%29 800
More Results